Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended June 30, 2022						Six Months Ended June 30, 2022
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	482	$	209	$	273	$	641	$	368	$	273
License Fee – Over time	65		—		65		127		—		127
Total Drug Products	547		209		338		768		368		400
Concentrate Products
Product Sales – Point-in-time	17,655		15,906		1,749		33,082		29,715		3,367
License Fee – Over time	480		480		—		956		956		—
Total Concentrate Products	18,135		16,386		1,749		34,038		30,671		3,367
Net Revenue	$	18,682	$	16,595	$	2,087	$	34,806	$	31,039	$	3,767

In thousands of U.S. dollars ($)	Three Months Ended June 30, 2021						Six Months Ended June 30, 2021
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	215	$	215	$	—	$	439	$	439	$	—
License Fee – Over time	58		—		58		117		—		117
Total Drug Products	273		215		58		556		439		117
Concentrate Products
Product Sales – Point-in-time	14,379		13,026		1,353		29,084		26,227		2,857
License Fee – Over time	485		485		—		971		971		—
Total Concentrate Products	14,864		13,511		1,353		30,055		27,198		2,857
Net Revenue	$	15,137	$	13,726	$	1,411	$	30,611	$	27,637	$	2,974

Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	June 30, 2022		December 31, 2021
Receivables, which are included in "Trade and other receivables"	$	8,090	$	5,913
Contract liabilities	$	7,274	$	8,157